Epocrates Drug Updates — Editor’s Pick
February 03, 2010
MedWatch Safety Alert for Didanosine
The FDA notified healthcare professionals about non-cirrhotic portal hypertension in patients using Videx or Videx EC (didanosine), a nucleoside reverse transcriptase inhibitor for treating HIV. Although rare, portal hypertension can cause serious complications, including death from hemorrhaging esophageal varices. The FDA believes the clinical benefits outweigh the potential risks for certain patients, and the decision to use this drug must be made on an individual basis.
MedWatch Safety Alert for Didanosine
Recent Updates
- January 27, 2010
- MedWatch Safety Alert for Meridia
Based on data that indicate an increased risk of heart attack and stroke in patients with a history of cardiovascular disease using Meridia (sibutramine), the FDA requested and the manufacturer agreed to add a new contraindication to the Meridia drug label. Meridia is not to be used in patients with a history of cardiovascular disease, including coronary artery disease, history of stroke or transient ischemic attack, history of arrhythmias, history of congestive heart failure, history of peripheral arterial disease, or uncontrolled hypertension. MedWatch Safety Alert for Meridia » - January 20, 2010
- New Drug Monograph for Fanapt
The FDA recently approved the atypical antipsychotic Fanapt (iloperidone) for the treatment of schizophrenia adult patients. New Drug Monograph for Fanapt » - January 6, 2010
- New Drug Monograph for Sumavel DosePro
The FDA recently approved a needle-free subcutaneous delivery system, Sumavel DosePro (sumatriptan), for acute migraine and cluster headache symptoms in adult patients. New Drug Monograph for Sumavel DosePro »
New Drug Monographs
RSS Feed
Top drug searchesThese updates, and hundreds more, are available in all Epocrates mobile and online products. See Products
To update your mobile reference, simply Update (sync). Learn How